Alternative trial design in amyotrophic lateral sclerosis saves time and patients
- 1 January 2007
- journal article
- clinical trial
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 8 (5), 266-269
- https://doi.org/10.1080/17482960701419497
Abstract
A sequential trial design is an alternative for the classical trial design with a fixed sample size, that permits stopping a trial as soon as enough evidence for a treatment effect, or a lack thereof, is obtained. This study aimed to determine the difference in efficiency of time and patient number between a classical trial design and a sequential trial design. In this study we re‐analysed a previously published classically designed clinical trial according to a sequential trial design. We subsequently determined the difference in total running time and patient number. We found that the sequential analysis offered a gain in time of 38%. We conclude that the sequential trial design may in certain situations be superior to the classical design.Keywords
This publication has 7 references indexed in Scilit:
- A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSNeurology, 2006
- High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJournal of Neural Transmission, 2004
- How a Sequential Design Would Have Affected the GAIN International Study of Gavestinel in StrokeCerebrovascular Diseases, 2003
- Monotherapy trials: sequential design.Epilepsy Research, 2001
- Incidence and prevalence of ALS in Ireland, 1995–1997Neurology, 1999
- The Design and Analysis of Sequential Clinical Trials.Biometrics, 1997
- Sequential or fixed sample trial design? A case study by stochastic simulationJournal of Clinical Epidemiology, 1991